pam50 breast cancer

Release time ：Dec-28,2024

Breast cancer is a prevalent malignant tumor, and the selection of treatment plans often relies on the molecular classification of the tumor. The PAM50 method, based on gene expression profiles, categorizes breast cancer into four subtypes: Luminal A, Luminal B, HER2-enriched, and Basal-like. These subtypes exhibit distinct biological features and clinical outcomes, making PAM50 classification essential for devising personalized treatment strategies.

Luminal A subtype is the most prevalent, comprising approximately 70% of all breast cancers. Tumors of this type are typically responsive to hormonal therapy and have a relatively favorable prognosis. The Luminal B subtype accounts for about 20% and, while also responsive to hormonal therapy, has a less favorable prognosis compared to Luminal A. The HER2-enriched subtype, making up about 15%, is characterized by the overexpression of the HER2 gene and has a poorer prognosis, although targeted therapies can improve outcomes. Lastly, the Basal-like subtype, also about 15%, generally has the poorest prognosis and lacks effective targeted treatment options.

In conclusion, PAM50 classification is not only instrumental in predicting the prognosis of breast cancer patients but also in guiding the choice of personalized treatment plans. It is, therefore, crucial for breast cancer patients to be aware of their PAM50 classification. Women should perform regular self-examinations of their breasts and undergo annual ultrasound or mammography screening. If any abnormalities are detected, they should promptly seek medical attention for further diagnosis and treatment under a physician's guidance. It is imperative not to self-medicate to avoid delaying the condition.